Perrigo launches store-brand equivalent to Claritin-D

ALLEGAN, Mich. — Perrigo on Tuesday announced that it has begun shipping Loratadine-D 12-hour extended-release tablets.

The new loratadine/pseudoephedrine combination formulation is the store brand equivalent to Merck Consumer's Claritin-D 12-hour extended-release tablets, which generates an approximate $111 million per year, according to Perrigo citing data provided by Wolters Kluwer.



The Loratadine-D store brand launch is the first of many new OTC products on Perrigo's launchpad this year, Perrigo chairman and CEO Joseph Papa said. "This launch is another milestone for our consumer healthcare segment, which is expected to launch many important new store brand products during this fiscal year," Papa said.

Interested in this topic? Sign up for our weekly Collaborative Care e-newsletter.